Isolated hypomethylated sites exist in the major breakpoint cluster region (M-bcr) where most Philadelphia chromosome (Ph) breakpoints are located. Twenty of 50 (40%) chronic myeloid leukemia (CML) patients were found to have aberrant hypermethylation of these sites on the rearranged Mbcr when compared with control marrows. The aberrancy correlated strongly with M-bcr breakpoint location; 19 of 20 cases had breakpoints located 5' of the M-bcr Sca I site, and 28 of 30 cases with normal M-bcr methylation had breakpoints located 3' of the M-bcr Sca I site. Sequence analysis of the Ph M-bcr breakpoints failed to find an M-bcr HRONIC MYELOID leukemia (CML) is a stem cell hematopoietic malignancy characterized by the t(9;22)."4 This karyotypic aberrancy is the result of an acquired, generally balanced translocation between the c-ab1 oncogene on chromosome 9 and the breakpoint cluster region (BCR) gene on chromosome 22 producing a BCR/cab1 hybrid gene. BCWc-ab1 fusion gene transcripts give rise to a hybrid protein that is essential in the pathogenesis of this disorder.'" Although numerous studies regarding the BCR/c-ab1 fusion gene product have been performed, few studies regarding the mechanism of the Philadelphia chromosome (Ph) translocation exist. Some studies have implied that chromosomal translocations occur randomly and that through selection only those that result in an oncogenic protein product will produce a neoplasm.8-12 Other investigators have sequenced areas adjacent to breakpoints in an attempt to find recumng sequence motifs that may mediate recombination. Although candidate sequences including Alu and chi-like elements have been identified in the proximity of chromosome breakpoints, no clear relationship of these sequences to breakpoint locations has been shown.13"'
HRONIC MYELOID leukemia (CML) is a stem cell hematopoietic malignancy characterized by the t (9;22) ."4 This karyotypic aberrancy is the result of an acquired, generally balanced translocation between the c-ab1 oncogene on chromosome 9 and the breakpoint cluster region (BCR) gene on chromosome 22 producing a BCR/cab1 hybrid gene. BCWc-ab1 fusion gene transcripts give rise to a hybrid protein that is essential in the pathogenesis of this disorder. '" Although numerous studies regarding the BCR/c-ab1 fusion gene product have been performed, few studies regarding the mechanism of the Philadelphia chromosome (Ph) translocation exist. Some studies have implied that chromosomal translocations occur randomly and that through selection only those that result in an oncogenic protein product will produce a neoplasm. [8] [9] [10] [11] [12] Other investigators have sequenced areas adjacent to breakpoints in an attempt to find recumng sequence motifs that may mediate recombination. Although candidate sequences including Alu and chi-like elements have been identified in the proximity of chromosome breakpoints, no clear relationship of these sequences to breakpoint locations has been shown.13" ' An alternate hypothesis suggests that the methylation status of chromosome regions may in some way be involved in the translocation Supporting this concept, an isolated 600-bp region of hypomethylation has been identified in hematopoietic cells in the major breakpoint cluster region (M-bcr) commonly involved in the Ph chromosome translocation on chromosome 22 (Fig 1) . This region becomes progressively hypomethylated during myeloid and lymphoid ont~geny.'~,'' In addition, this region is abnormally methylated in the hematopoietic cells in a number of patients with chronic myeloid l e~k e m i a .~~. '~.~~ It is the characterization of this abnormality that is the basis for these current investigations.
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MATERIALS AND METHODS
M-bcr methylation analysis-Southern blot.
Genomic DNA extracted from bone marrow samples from 50 patients with CML in chronic phase and 8 patients with CML in morphologic and molecular remission after interferon therapy and/or autologous bone marrow transplantation were used in this study. The specimens were obtained at the University of Minnesota Hospital from 1988 to 1995 with approval from the Institute's Internal Review Board on the Use of Human Subjects in Biomedical Research. In addition, genomic DNA specimens extracted from 1 1 morphologically normal bone marrows were used as controls. DNA was extracted by routine organic phase methods with proteolytic and ribonucleolytic steps, as described previously."
Five to ten micrograms of DNA from each sample was digested with 8 to 10 U/pg of the various restriction endonucleases (GIBCO Life Technology, Inc, Bethesda, MD) according to the manufacturer's recommendations. Because of its very short shelf life, only BspHI (New England Biolabs, Inc, Beverly, MA) that was less than 2 weeks old was used in these studies. Those samples requiring additional Hpa I1 digestion were then ethanol precipitated and the restriction fragments were redigested with 5 to 10 U/pg DNA Hpa I1 according to the manufacturer's recommendations (GIBCO Life Technology, Inc). Conventional electrophoresis was performed in horizontal 0.7% agarose gels. Standard methods were used for transferring electrophoretically separated restriction fragments to nylon membranes (Genescreenplus; Dupont, Inc, Wilmington, DE).
The following probes were used in this study: the 5' Taq VHindIll M-bcr probe is the 5' most 1,200-bp Taq VHindIII fragment of the M-bcr ( Fig I) ; this probe was isolated from the bcr Pr-l probe, which is the 5' most Bgl IYHindIII 2.0-kb fragment of the M-bcr inserted into the Hind111 site of PUC 12.21 The HindIIVMsp I Mbcr probe is the 250-bp M-bcr HindIIUMsp I fragment including most of M-bcr exon 2 (b2 or BCR gene exon 13; see Fig 5) . It was derived by Msp I digestion and gel electrophoresis of a polymerase chain reaction (PCR)-amplified fragment that included M-bcr exon 2 (b2), M-bcr intron, and exon 3 (b3), as previously described. 22 Probe pSPT/pGK is the 800-bp BamHIIEcoRI fragment inserted into the BamHVEcoRI sites of PSP 64 identifying alleles at the PGK locus on chromosome X."
All probes were 32P radiolabeled using the random primer reaction. The filters were prehybridized, hybridized, and rehybridized, if necessary. under standard conditions according to the manufacturer's recommendations (GeneScreenPlus; Dupont, Inc Densitometry was performed on a digitalized, video image of the illuminated autoradiograms using the Quick Capture frame grabber board and software (Data Translation, Inc. Marlboro, MA ) in conjunction with a Macintosh IIci computer.
Sequencing M-bcr breakpoints in CML cuses with Ph breakpoints localized to rhe BspHIBca I M-bcrfragment. Sequencing across Ph breakpoints was performed by two methods. The first is a modified inverse PCR technique and has been described previo~sly.~~ The methylation and breakpoint data from the case sequenced in that publication are presented in this aggregate data.
The second method is a modification of an anchor PCR technique described by Luo and Cella.25 Briefly, 5-pg aliquots of marrow DNA from the cases with Ph breakpoints in the M-bcr BspHVScu I fragment and from normal control individuals were digested with 6 to 8 restriction endonucleases that included BumHI, Bgl 11, Dpn I, Mae 11, Msp I. Psr I, Scu I, and Tuq I. These specimens were ethanol precipitated, washed with 70% ethanol, lyophilized, and diluted with 50 pL TE. Using 1 U of T4 DNA ligase in a 10 pL total reaction volume, 200-ng aliquots of each of these genomic digests were ligated at 15°C overnight with 100-ng aliquots of dephosphorylated PUC19 cleaved with the appropriate compatible endonuclease and column purified (Wizard DNA clean up system; Promega, Inc. Madison, W). The ligation buffer conditions were according to the manufacturer's recommendation (GIBCO BRL Life Technologies, Inc. Gaithersburg, MD) with polyethylene glycol (PEG-8000) and cobalt chloride added to final concentrations of 10% and 1 pm, respectively.
The ligation mixtures were heated to 70°C for 30 to 60 minutes to inactivate the ligase and 40 p L of TE was added. One microliter from each of these ligation mixtures was PCR amplified using a seminested PCR technique. The primers used in the first round of amplification were derived from sequences of the M-bcr and PUC19 sequence, ie, primer A, A'IT ACA C'lT CGA GTC ACT G G , and primer B, 'ITC ACA CAG GAA ACA G, respectively. The template was amplified using the following conditions: 1 X Taq polymerase buffer (Perkin-Elmer, Inc. Nonvalk, CT), 3.5 mmoVL MgC12, 0.01% gelatin, 200 pmoVL dNTP, 0.2 pmoVL primer A, and 0.2 pmoVL primer B. Cycling parameters were as follows: initial denaturing at 94°C for 3 minutes followed by 35 cycles of 94°C for 1 minute, 60°C for 1 minute, and 72°C for 90 seconds. This was followed by a terminal extension step of 72°C for 10 minutes. One microliter of the resulting PCR mixture was used as the template for the second round of amplification. The same primer to the PUC19 (primer B) was used in this PCR; however, the second primer. primer C, was different from that used in the first round of amplification and consisted of a sequence internal (3') to the first M-bcr primer, ie, primer C, TGT A'IT GTG AAA CCA ACT GG. The resulting second-round PCR product from the control and CML marrows were analyzed on a nondenaturing 5% polyacrylamide gel. Amplified fragments not present in the control marrows were cloned and sequenced and compared with the previously sequenced M-bcr to precisely localize the Ph breakpoint.
Verijcurion of presence of the 2.5-kb M-bcr Hpa I1 site. The 2.5-kb M-bcr Hpu I1 recognition sequence (CCGG) was verified to be intact by Msp I digestion of a PCR-amplified product encompassing this site; Msp I is a methylation insensitive isoschizmer of Hpu 11. Briefly. 0.1 pg of genomic DNA from each of the 11 cases with abnormal M-bcr methylation and with Ph breakpoints 3' of the BumHI site indicated in Fig 4 and with abnormal M-bcr methylation were subjected to a single-round PCR using the same reaction conditions and parameters described above. The primers used were as follows: (A) CG CTG ACC ATC AAT AAG GAA and (B) CCA G'IT GGT 'ITC ACA ATA CA. The primers recognize and amplify a 550-bp intronic fragment between M-bcr exons 2 and 3. The amplified fragment is 5' of the M-bcr BumHI site and encompasses the 2.5-kb M-bcr Hpu I1 site; the position of these primers, therefore, assures amplification of both the unrearranged and Ph 2.5-kb Hpu I1 site. This fragment was then digested with Msp I (20 U/pg PCR amplimer; GIBCO Life Technology, Inc). The complete digestion of the 550-bp fragment to two fragments, 160 bp and 390 bp, as determined on a nondenaturing 5% polyacrylamide gel, indicated that the Hpu II recognition sequence was intact on both the Ph and unrearranged chromosome 22.
RESULTS
M-bcr methylation status of patients with CML in chronic phase. It has previously been shown that the methylation status of the M-bcr varies with the cell type and maturation in the marr~w."~'**~ For this reason, only individuals that were in morphologic chronic phase were examined. Aspirates of the marrow were examined by a hematopathologist (C.E.L.) to ascertain relative uniformity of cell composition from case to case. Differential cell counts were also performed for later statistical analysis (infra vide). Individuals in blast crisis or accelerated phase according to Southwestern
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From 
B B M 5' M-bcr Probe
Oncology Group (SWOG) criteria were excluded from study. The M-bcr methylation status of 50 CML cases was studied. As controls, I 1 morphologically normal bone marrows from individuals with nonhematologic disorders were examined; these control marrows did not have a rearranged M-bcr by Southern blot analysis (data not shown).
The normal control marrows showed a uniform and distinct M-bcr methylation pattern with four major restriction fragments (Fig 2) . The first fragment was 4.8 kb in length and represented the intact Bgl IIIBgI I1 M-bcr fragment with no Hpa I1 digestion. Densitometrically, this fragment comprised 10% t 2.5% ( l SD) of the lane signal (Figs 3 and   4) . The second and third fragments were 3.0 kb and 3.1 kb in length. As shown previously, these fragments represent Bgl IIIHpa I1 M-bcr fragments, with the digested Hpa I1 site occumng 3.0 and 3.1 kb 3' of the 5' most M-bcr BgI I1 site, kb and, in toto, comprised less than 10% of the lane signal. These fragments have been previously described and likely represent minor cell populations such as B lymphocytes, monocytes, and megakaryocyte^.'^^'^^'" All of these fragments have been previously shown to represent separate, distinct methylation forms or alleles of the M-bcr distributed among the various diploid hematopoietic cells."~'* The marrow specimens from some patients with CML showed an additional allele using the Southern assay. This allele was the hypermethylated, rearranged M-bcr Bgl IVBgl I1 fragment that was resistant to Hpa I1 digestion (Fig 2) . This allele comprised from 0% to 66% of the lane signal of CML patient samples. The frequency distribution of the lane signal percentage of this allele showed a bimodal distribution, with 20% lane signal as the cutoff value for discrimination between the two groups (Fig 3) . This represents the basis for the two different M-bcr methylation patterns noted in the CML marrow specimens.
The first M-bcr methylation pattern (pattern l), noted in 30 of 50 CML cases (60%), was similar to that of the control marrows (Figs 2 and 3) . The 4.8-kb, 3.1/3.0-kb, and 2.5-kb alleles were present in proportions that were not statistically different from the control values (1 1% t 6%, P = .70; 49% t lo%, P = .35; 32% It 8%, P = .65). The hypermethylated rearranged Bgl IUBgl I1 fragment was present in statistically significant lower proportions to the unrearranged hypermethylated Bgl IYBgZ I1 fragment (6% t 6%, P < ,005).
The second M-bcr methylation pattern (pattern 2) was noted in 20 of 50 CML cases (Figs 2 and 3) . In these cases, aberrantly hypermethylated, rearranged M-bcr Bgl IYBgl I1 alleles were present in significantly greater proportions than the unrearranged hypermethylated 4.8-kb BgZ IVBgl I1 frag-
The unrearranged 4.8-kb allele in these cases comprised a significantly higher proportion of the lane signal than the control marrows (19% t 13% v 10% t 2.5% [P < .01], respectively). The 3.1/3.0-kb and 2.5-kb alleles in these cases comprised, on average, one-half of the lane signal when compared with the control cases and were significantly different from the control values (20% t lo%, P < .001, and 16% ? 9%, P < .001, respectively).
To ascertain that these differences in methylation were not due to differences in cell composition of the specimen, 1,000 cell differential counts were performed on all CML marrow samples from which the DNA was derived and a statistical analysis was performed (Table 1 ). There were no statistically significant differences in cell composition of the aberrantly methylated cases when compared with the normally methylated cases.
Comparison of M-bcr breakpoint location to M-bcr methylation status. To address whether the Ph M-bcr breakpoint location influenced the Southern blot-determined Ph M-bcr methylation status, the Ph breakpoints were restriction mapped for each of these 50 CML cases. Assignment of Ph breakpoints was made without using the assumption of reciprocal translocation, thereby excluding the confounding effect that small deletions or duplications may have on breakpoint pla~ement.'~ Breakpoints were assigned to one of six M-bcr subregions shown in (Fig 4) . Using the M-bcr BspHVSca I fragment as the point of reference, there is a statistically significant correlation of breakpoint location with methylation pattern ( P < .001; Fischer exact test). Those with breakpoints 5' of the BspHI site had abnormal methylation patterns (pattern 2) and those with breakpoints 3' of the Sca 1 site had normal methylation patterns (pattern l), with one exception. Cases with breakpoints within the BspHIISca I fragment had transitional methylation patterns.
One of 20 cases with pattern 2 (abnormal) M-bcr methylation had a Ph breakpoint located 3' of the M-bcr Sca I site in the HindIIUBgl I1 fragment. This case had a threshold abnormal methylation pattern, with the hypermethylated rearranged M-bcr Bgl IVBgl I1 fragment comprising 22% of the lane signal.
Twelve of the 20 cases with aberrant (pattern 2) methylation had Ph breakpoints that were located 3' of the indicated Taq I site in Fig l . This Taq I site is located within the Mbcr hypomethylated region, 200 bp 3' of the 2.5-kb M-bcr Hpa I1 site. A Ph M-bcr breakpoint located 3' of this Taq I site, therefore, implies that the Ph M-bcr contains at least the 5' portion of the hypomethylated region (the 2.5-kb Hpa I1 site). The M-bcr methylation aberrancy detected by this Southern assay is, therefore, not solely due to the translocation of the hypomethylated Hpa I1 sites to the 9q+ chromosome in these instances.
Eleven of these 12 cases were examined for the presence of the Hpa I1 recognition sequence, CCGG, by Msp I digestion of PCR amplification products encompassing the 2.5-For personal use only. on June 9, 2017. by guest www.bloodjournal.org From . In all I 1 cases, this sequence was confirmed to be present. indicating that the lack of Hpa 11 digestion was not due to the mutation of the recognition sequence.
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on one allele is associated with M-bcr Itypermethylation in CML. In the cases with aberrant rearranged M-bcr methylation and M-bcr breakpoints located 3' of the M-bcr Taq I site indicated in Fig 1, the 2.5-kb Hp0 11 site is intact. To verify that this Hpa 11 site is aberrantly hypermethylated in these cases and that the hypermethylation is confined to one allele, as would be expected in the case of a hypermethylated rearranged M-bcr, Southern blot assays using Tay IlHpa 11 double digests were performed (Fig 5) . The Tny I site 1.2 kb 5' of the above Tay I site is a common restriction site polymorphism in the general population (Fig S) ." Because the 2.5-kb Hp0 11 site is located between a polymorphic and nonpolymorphic Toy I site, Southern blots of Tlry IlHpa 11 double digests of marrow cell DNA from individuals heterozygous for the Tay I polymorphism probed with the HindlIIlMsp I M-bcr probe result in four fragments: the Tay I allele A without or with digestion of the 2.5-kb Hpa I1 site and the Tuq I allele B without or with digestion of the 2.5-kb Hpa 11 site (Fig 5) . The fragment lengths for these various possible combinations are 1.9 kb, 1.7 kb, 1.2 kb, and 1.0 kb, respectively. The 3.0/ 3.1-kb RgI IIIHpcr 11 alleles and the 4.8-kb and rearranged hypermethylated RgI 1IIRgI 11 alleles do not have digestible 2.5-kb Hpcr I1 sites present and. therefore, these alleles comprise the 1.9-kb and 1.2-kb Taq IIHpa I1 alleles.
Ten of the CML marrow specimens with Ph M-bcr breakpoints 3' of the Taq I site and four of the normal marrow specimens were found to have informative M-bcr Tay I polymorphisms. Six of the CML specimens had pattern 1 (normal) M-bcr methylation and four had pattern 2 (aberrant) M-bcr methylation.
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Southern blots of Tay IIHpa 11 digests of the normal marrow control specimens using the HindIIlIMsp I M-bcr probe showed that the two Taq I alleles with the 2.5-kb Hpa I1 sites were present in equal proportions, ie, the allelic lane signal ratio of Tay 1,Hpa I12.,tJTay IhHpa 112.5kh was 0.95% ? 0.1% (mean ? SD; Fig 5) . This indicates that the 2.5-kb Hpa 11 site does not show an allelic preference in normal marrow; both copies of the M-bcr are hypomethylated to the same degree in myeloid cells with respect to the 2.5-kb Hp0 I1 site.
Southern blots of Tay IlHpo II digests of the CML patients with pattern 1 (normal) M-bcr methylation using the HindIIIl Msp I M-bcr probe showed a Taq 1,Hp I12,5ktJTaq IhHpa Ilz.5kh allelic lane signal ratio of 1.02 ? 0.22 (mean 2 SD: Fig 5) . This is not significantly different from the normal marrow control value ( P = .S) and indicates that the 2.5-kb Hpa 11 site does not show allelic preference in the pattern I CML cases.
The same study with the four aberrantly methylated CML patients (pattern 2) showed Trrq I:,Hprr 112,5ktJTaq I,,Hpo I12.5kh allelic lane signal ratios of 0.10. 0.49, 1.69, and 2.68 ( Fig  5) . Each of these values was significantly different than the normal marrow control values ( P < .005). indicating that there is an allelic preference of the 2.5-kb M-bcr Hpn 11 site in the pattern 2 CML cases. This confirms that there is aberrant hypermethylation of the 2.5-kb M-bcr Hpa I1 site on one allele, as would be expected on the hypermethylated rearranged M-bcr.
M-hcr metk.vlntion status of cases with Plt breakpoints localized to the M-hcr BspHIBca I fragment. Nine of 50 CML cases had Ph M-bcr breakpoints localized to the 241 -bp BspHIlSca I fragment (Figs 1 and 4) . The M-bcr methylation patterns of these cases were mixed: 2 of 9 showed a normal (pattern 1) and the remaining 7 showed an abnormal (pattern 2) M-bcr methylation pattern. The presence of both methylation patterns in cases with Ph breakpoints located in this All values are group means. Statistical analyses were performed using the analysis of variance (ANOVA). Abbreviation: NS, no significant difference between the groups was observed at the 95% confidence interval.
* Neutrophils, rnetamyelocytes, and myelocytes.
region suggested that a sequence critical for a normal Mbcr methylation pattern might be present in this area. If the sequence was present on the Ph, a normal methylation pattern would result; if it was translocated to the 9q+, an aberrant pattern would result.
To address this issue, the M-bcr breakpoints of S of these cases were precisely located by sequence analysis using ligation-PCR techniques. Two of these cases had a normal Mbcr methylation pattern (pattern I) and three had an aberrant pattern (pattern 2). The results of this study are indicated in the lower portion of Fig 1. There was no correlation of breakpoint location and Mbcr methylation pattern within the BspHVSca I region. The two cases with normal M-bcr methylation patterns had Ph breakpoints located 5' of two cases with aberrant methylation patterns (Fig l) . In addition, there were no sequence differences in the M-bcr regions adjacent to the Ph breakpoints in the BspHIISca I fragment in any of these cases. This indicates that the absence of a specific sequence motif in this region due to translocation was not responsible for the aberrant methylation.
M-bcr methylation abnormalities of patients with CML in molecular remission (post-autologous bone marrow transplantation andor interferon therapy).
The purpose of these studies was to address whether the aberrancy in M-bcr methylation may be present in Ph-cells of CML patients. These cells were collected from individuals with CML who were treated with a-interferon or autologous marrow transplantation. These therapeutic modalities frequently suppress the Ph+ clone while allowing a selective advantage to the normal Ph-background hematopoiesis." All patients examined were in morphologic and molecular remission and had similar marrow cell composition ( Table 2 ). The molecular remission was defined as specimens containing 25% or less Ph' cells; this was ascertained by densitometric quantitation of Southern blots assaying M-bcr rearrangement status of a specimen.
DNA from bone marrow samples of eight individuals fulfilling the above criteria were examined. Figure 6 shows the findings. Three showed an abnormal M-bcr methylation pattern. The 4.8-kb hypermethylated BgL IVBgL I1 allele in all three of these specimens comprised greater than 3 SD of the control value for lane signal (S4%, 43%, and 30% v 10% ? 2.5% [l SDI, respectively) and the 3.1/3.0-kb allele lane signal intensity was less than 3 SD from the control mean value (18%, 25%, and 29% v 50% 2 6.5% [l SDI, respectively). This indicated that the M-bcr was hypermethylated in these cases due to a relative resistance to Hpa I1 digestion of the 3.1/3.0-kb Hpa I1 sites; the 2.5-kb allele was within 2 SD of the control value (20%, 32%, and 34% v 31% 2 6.5% [ 1 SDI) . The remaining five cases showed methylation patterns that were within 2 SD of the control values of the lane signals for all M-bcr methylation alleles.
Ph M-bcr breakpoint restriction mapping was available on four of the above-mentioned cases when the patient was in the chronic phase of CML, one with the abnormal M-bcr methylation pattern and three with the normal M-bcr methylation pattern in the remission marrow specimens. In the one remission case with an abnormally methylated germline Mbcr, the breakpoint was located 5' of the M-bcr Sca I site when in chronic phase. This case also had aberrant M-bcr methylation (pattern 2) documented when in chronic phase. One of the three normally methylated cases had an M-bcr breakpoint located 5' of the Sca 1 site but 3' of the BspHl site and two had M-bcr breakpoints located 3' of the Sca I site when in chronic phase (Fig 6) .
The aberrant M-bcr methylation noted in the three remission marrows above could not formally be attributed to the rearranged allele due to the lack of informative restriction fragment polymorphisms in the region.
DISCUSSION
The M-bcr has been described as aberrantly methylated in CML patients by three investigator^.^^,^^,^^ The original description in this laboratory showed 3 of 20 CML cases in chronic phase (15%), in which the rearranged M-bcr appeared to be aberrantly hypermethylated. However, restriction mapping of the M-bcr breakpoint location with respect to the hypomethylated region was not performed, and it could not be determined whether this was due to the simple translocation of the involved M-bcr Hpa I1 sites to the 9q+ chromo~ome.'~ Mills et ally showed that all CML patients had aberrant M-bcr methylation at some time during their disease course. However, the morphology was not compared with the M-bcr methylation status in any of the marrow samples and the confounding influence of myeloid cells at earlier stages of maturation, as is commonly seen in CML accelerated and blast crisis on the M-bcr methylation status, could not be controlled for. In addition, M-bcr breakpoint mapping was not performed with respect to the M-bcr BspHI and Sca 1 sites and conclusions regarding the influence of M-bcr breakpoint location on aberrant M-bcr methylation could not be made." Ohyashiki et a1'" showed aberrant methylation of the rearranged M-bcr in 8 of 20 (40%) CML cases. in Ph positive cells
The morphology in these cases was controlled, but restriction mapping of the M-bcr breakpoint with respect to the BspHI and Sca I sites was not performed and no conclusions regarding the relationship of M-bcr breakpoint location with methylation aberrancy could be made. These investigators substantiated the relationship between morphology of the specimen and the M-bcr methylation pattern. The M-bcr methylation status of 50 Ph' CML patients in chronic phase with morphologically equivalent bone marrow specimens was determined in the current study. Twenty cases (40%) showed clearly aberrant M-bcr methylation of the rearranged allele. There was a strong association of M-bcr breakpoint location with methylation status of the rearranged M-bcr. With one exception, all cases with aberrant M-bcr methylation had Ph breakpoints located 5' of the M-bcr Sca I site. All cases with normal M-bcr methylation patterns had M-bcr breakpoints located 3' of the M-bcr RspHI site.
A trivial explanation for this association is that all potential M-bcr Hpa I1 sites were translocated to chromosome 9 in those cases with M-bcr breakpoints located 5' of the Mbcr S C~ I site. These studies indicate that this is not the case. At least 12 It is possible that the M-bcr methylation abnormality may have preceded rather than resulted from or succeeded the translocation event. To this end, we sought evidence of abnormal methylation in Ph-cells in patients with CML. These cells are commonly present in very small numbers in patients with CML in chronic phase; however, after treatment with autologous bone marrow transplantation or interferon, cases with large numbers of Ph-cells are frequent.26 Evidence of aberrant M-bcr methylation in Ph-cells was observed in three of eight cases; however, the lack of useful polymorphic restriction sites in this region did not allow the assignment of this methylation abnormality to the M-bcr that underwent rearrangement. In the cases for which Ph breakpoint data were available, the methylation patterns of unrearranged Mbcrs in the remission specimens showed the same association with M-bcr breakpoint location as the chronic phase specimens. These preliminary findings support the concept that the methylation aberrancy may precede the translocation event.
The relationship of DNA methylation to recombination is currently ill-defined; however, there are several instances in which hypomethylated sequences have been described in regions adjacent to and overlapping areas undergoing both physiologic and pathologic rec~mbination.~"~~ The T-cell receptor 0 chain gene has been found hypomethylated when aberrantly rearranged in acute lymphoid and myeloid leuke- In their proposed model, a change in methylation status may be associated with a change in chromatin configuration and chromatin accessibility to the cell's recombinatorial machinery. This model is attractive in that it provides an explanation for the physiologic changes in M-bcr methylation during hematopoietic cell development. Changes in M-bcr chromatin configuration may be necessary for normal hematopoietic DNA replication, cell division, and differentiation; DNA methylation may effect such a change. It is tenable that aberrancies in methylation, either hypermethylated or hypomethylated states, may be associated with aberrant chromatin configurations capable of erratic recombinatorial events.
Whereas abnormal M-bcr methylation occurred in 40% of CML cases, the remaining 60% showed no aberrancy. The reason for this is currently not known; however, methylation aberrancies in the c-ab1 oncogene on chromosome 9, the partner gene in the reciprocal translocation, were not sought in this study. c-ab1 breakpoints are difficult to analyze in this disease by conventional Southern methods: It is possible that c-ab1 methylation abnormalities may be present in the CML cases showing normal M-bcr methylation. A recent study examining the methylation status of the c-ab1 oncogene promoter regions in patients with CML in chronic phase found evidence of abnormal partial c-ab1 hypermethylation in 4 of 14 of cases; however, no data with regards to M-bcr methylation status or M-bcr breakpoint location were given in these cases and a relationship of the methylation status of the two genes could not be establi~hed.~~
The role that Ph M-bcr methylation status may have in disease course is not addressed by these studies. The main therapeutic modality of marrow transplantation at our institute for most of these cases did not allow adequate follow-up data on the natural history of these cases. Although several investigations have indicated a role for M-bcr breakpoint location in disease course, others have not.3s In these reports, the presence or absence of M-bcr exon 111 in the BCWabl hybrid product was considered the important distinguishing feature. Mills et ally suggested that the Ph M-bcr methylation status may be the important feature and that it may have a role in overall BCWabl expression. This will require further studies on untransplanted patients for confirmation.
